Cargando…

Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study

BACKGROUND: The Trastuzumab for Gastric Cancer (ToGA) study is the first international trial to include Japanese patients with human epidermal growth factor 2 (HER2) positive advanced/metastatic gastric or gastroesophageal junction cancer. ToGA showed that trastuzumab plus chemotherapy (capecitabine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sawaki, Akira, Ohashi, Yasuo, Omuro, Yasushi, Satoh, Taroh, Hamamoto, Yasuo, Boku, Narikazu, Miyata, Yoshinori, Takiuchi, Hiroya, Yamaguchi, Kensei, Sasaki, Yasutsuna, Nishina, Tomohiro, Satoh, Atsushi, Baba, Eishi, Tamura, Takao, Abe, Takashi, Hatake, Kiyohiko, Ohtsu, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3390686/ https://www.ncbi.nlm.nih.gov/pubmed/22179434 http://dx.doi.org/10.1007/s10120-011-0118-1

Ejemplares similares

Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study
por: Yamaguchi, Kensei, et al.
Publicado: (2012)

Erratum to: Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study
por: Yamaguchi, Kensei, et al.
Publicado: (2012)

Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm
por: Sawaki, Akira, et al.
Publicado: (2017)

Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial
por: Shiroiwa, T, et al.
Publicado: (2011)

Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer
por: Doi, Toshihiko, et al.
Publicado: (2010)

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer
por: Muro, Kei, et al.
Publicado: (2023)

Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer
por: Shitara, Kohei, et al.
Publicado: (2021)

Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
por: Satoh, Taroh, et al.
Publicado: (2019)

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2016)

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
por: Chung, Hyun Cheol, et al.
Publicado: (2020)

A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2)
por: Kato, Ken, et al.
Publicado: (2018)

Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial
por: Tabernero, Josep, et al.
Publicado: (2022)

Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study
por: Yoshikawa, Akie Kimura, et al.
Publicado: (2022)

Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)
por: Kawamoto, Yasuyuki, et al.
Publicado: (2022)

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
por: Van Cutsem, Eric, et al.
Publicado: (2014)

Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients(†)
por: Boku, Narikazu, et al.
Publicado: (2014)

A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma
por: Ooki, Akira, et al.
Publicado: (2022)

New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
por: Rose, Jeffrey S, et al.
Publicado: (2011)

Coexistence of Gastric Adenocarcinoma and Choriocarcinoma: Complete Response to Trastuzumab and Chemotherapy
por: Gunduz, Seyda, et al.
Publicado: (2012)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Nestin overexpression reduces the sensitivity of gastric cancer cells to trastuzumab
por: Wei, Yi-Chou, et al.
Publicado: (2023)

HER2-positive gastric cancer
por: Boku, Narikazu
Publicado: (2013)

Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study
por: Matsumoto, Toshihiko, et al.
Publicado: (2022)

Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial
por: Shitara, Kohei, et al.
Publicado: (2019)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki, Masataka
Publicado: (2014)

Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer
por: Arienti, Chiara, et al.
Publicado: (2016)

Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines
por: Keller, Simone, et al.
Publicado: (2018)

Prediction of key genes and pathways involved in trastuzumab-resistant gastric cancer
por: Yu, Chaoran, et al.
Publicado: (2018)

Bioinformatics Analysis of Potential Key Genes in Trastuzumab-Resistant Gastric Cancer
por: Yang, Guangda, et al.
Publicado: (2019)

Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
por: Kotani, Daisuke, et al.
Publicado: (2021)

Overexpression of GSE1 Related to Trastuzumab Resistance in Gastric Cancer Cells
por: Wang, Wenbin, et al.
Publicado: (2021)

A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients
por: Zhu, Bo, et al.
Publicado: (2015)

Synergistic antitumor effect of the anti-ErbB2 antibodies trastuzumab and H2-18 on trastuzumab-resistant gastric cancer cells
por: Wang, Chao, et al.
Publicado: (2021)

El alma de la toga
por: Ossorio y Gallardo, Ángel, 1873-1946
Publicado: (2005)

La toga y la palabra
Publicado: (1997)

El alma de la toga /
por: Ossorio y Gallardo, Angel, 1873-1946
Publicado: (1971)

Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07)
por: Satoh, Taroh, et al.
Publicado: (2021)

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
por: Wakatsuki, Takeru, et al.
Publicado: (2018)

A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
por: Chen, Li-Tzong, et al.
Publicado: (2019)

Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)
por: Kurokawa, Y, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_h3noisp041p5pc5c6dvlsi3jdp